Lina Rossetti-Grulich
Acute Care · Portland, ORNPI 1225639040
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,136 of the $7,561 with a category attached, or 81.2%. It is spread thinly across 26 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,830, more than ten times the $237 reported in 2021. Among acute care clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $56.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Cvrx, Inc.$1K
- Abiomed$927
- Abbott$682
- Boston Scientific$517
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$436
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,21816%
- Food & beverage$6,13681%
- Education$2073%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $1,406 |
| Cvrx, Inc. | 9 | $1,399 |
| Abiomed | 15 | $927 |
| Abbott | 5 | $682 |
| Boston Scientific | 4 | $517 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $436 |
| Novo Nordisk | 6 | $351 |
| Impulse Dynamics (USA) Inc. | 7 | $337 |
| Boehringer Ingelheim | 2 | $206 |
| Alnylam Pharmaceuticals Inc. | 3 | $183 |
| Lexicon Pharmaceuticals, Inc. | 2 | $182 |
| Merck | 6 | $168 |
| Endotronix, Inc. | 1 | $157 |
| E.r. Squibb & Sons, L.L.C. | 4 | $101 |
| Amgen | 4 | $89 |
| Edwards Lifesciences | 3 | $85 |
| Bridgebio Pharma, Inc. | 4 | $71 |
| Pfizer | 2 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $48 |
| Novartis | 2 | $38 |
| Scpharmaceuticals Inc. | 1 | $32 |
| Bayer | 1 | $26 |
| Teleflex LLC | 1 | $22 |
| Heartflow, Inc. | 1 | $21 |
| Sanofi | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$1,155
- MitraClip$521
- WATCHMAN Access System$481
- OPTIMIZER$474
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$157
- CARDIOMEMS$151
- Impella$130
- JARDIANCE$125
- FARXIGA$125
- Wegovy$122
- AMVUTTRA$120
How this compares
$7,561 in reported general payments places this provider in the 95th percentile of 105 acute care providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 26 | $561,340 |
| EntrestoSacubitril/Valsartan | 446 | $477,543 |
| JardianceEmpagliflozin | 266 | $251,082 |
| FarxigaDapagliflozin Propanediol | 178 | $188,049 |
| EliquisApixaban | 166 | $187,002 |
| FuroscixFurosemide | 11 | $39,956 |
| XareltoRivaroxaban | 29 | $38,326 |
| VerquvoVericiguat | 25 | $29,365 |
| DapagliflozinDapagliflozin Propanediol | 24 | $14,339 |
| Metoprolol Succinate | 370 | $4,278 |
| Torsemide | 220 | $3,686 |
| Potassium Chloride | 137 | $2,103 |
| Isosorbide Dinitrate | 40 | $2,040 |
| Atorvastatin Calcium | 128 | $1,597 |
| Rosuvastatin Calcium | 158 | $1,528 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $48 | $748,342192 claims |
| NovartisEntresto | $38 | $477,543446 claims |
| Boehringer IngelheimJardiance | $206 | $251,082266 claims |
| AstraZenecaFarxiga | $1,406 | $188,049178 claims |
| Scpharmaceuticals Inc.Furoscix | $32 | $39,95611 claims |
| MerckVerquvo | $168 | $29,36525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 acute care providers in Oregon.
Other acute care in Portland
- Robin MillerPortland$74K
- Jacqueline TrussellPortland$15K
- Aura PetcuPortland$3K
- Jamie FungPortland$2K
- Amy AlbertsPortland$2K
- Lynzy Elzinga WeekesPortland$2K
- Benjamin HartwigPortland$1K
- Kristyn DemelloPortland$1K
- Dana MoussalliPortland$1K
- Melissa SkinnerPortland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.